-
Event
What is up for biopharmaceutical policy in 2024?
11.20.2023
Incubate and DLA Piper invite you to join us on the morning of Sunday, January 7th, as part of JPM Week 2024.
-
Blog
Mary R. Grealy on the Small Molecule Penalty, U.S. Dominance in Life Sciences, and More
10.12.2023
Incubate Executive Director John Stanford sat down this week with Mary R. Grealy, CEO of the Healthcare Leadership Council, to discuss the latest developments in health policy on the Making Medicine podcast.
-
Statement
Incubate releases statement on Fitch Ratings’ analysis of Medicare drug price negotiations
09.26.2023
Fitch Ratings recently released an analysis showing that Medicare's drug price negotiation program is expected to deter investments into small molecule drugs.
-
Blog
Medicare presses forward with drug price setting
09.18.2023
In late August, the Centers for Medicare & Medicaid Services announced the first 10 drugs that will be subject to Medicare price setting under last year's Inflation Reduction Act.
-
Blog
Mohit Manrao Talks Small-Molecule Penalty, Eliminating Cancer as a Cause of Death, and More
09.15.2023
The small-molecule penalty "doesn't create the right incentives for where we want to go with the Cancer Moonshot or driving cures," Mohit reflected.
-
Video
-
Statement
Incubate releases video explainer on small molecule penalty
09.13.2023
Incubate released a video explaining how the small molecule penalty in recently passed legislation will negatively impact medical research and innovation.
-
Statement
Life sciences investors react to first 10 drugs selected for government price controls
08.29.2023
Executive Director John Stanford issued a statement in response.
-
Comment
Incubate Comment in Response to NIH Technology Transfer Workshop
08.25.2023
Incubate submitted this comment on August 18, 2023.
-
Statement
New legislation would spread the disease of price controls to more treatments and cures
07.26.2023
Incubate Coalition executive director John Stanford issued the following statement in response to the introduction of the Lowering Drug Costs for American Families Act:
-
Comment
Incubate Submits Comment in Response to Draft Legislation to Reauthorize PAHPA
07.10.2023
Incubate recently submitted comment in response to the Senate HELP Committee’s draft legislation to reauthorize the Pandemic and All-Hazards Preparedness Act (PAHPA).
-
Statement
CMS’ Final Guidance on Medicare Drug Price Negotiation Program Offers Some Clarity, But Misses Opportunity to Address the Small Molecule Penalty
07.06.2023
Executive Director of Incubate, John Stanford, issued the following statement regarding the release of the Centers for Medicare and Medicaid Services’ (CMS) final guidance on the Medicare Drug Price Negotiation Program.
Resources
